Pharma BD Deal Intelligence

Biogen Idec Inc. / Elan Corporation plc (Tysabri rights)

2013 · Asset Purchase · $3.2B · Complete

Announcement Sentiment

100

Strongly positive

Biogen Idec acquired full rights and control of Tysabri from Elan for $3.25B upfront plus tiered royalties (12%/18%/25%); originally announced Feb 6, 2013 and closed Apr 2, 2013.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 10yr post-close.

Key facts

Announced Apr 02, 2013
Closed Apr 02, 2013
Deal value $3.2B
Deal type Asset Purchase
Therapeutic area Multiple Sclerosis (relapsing forms) and Crohn's Disease
Indications Multiple Sclerosis (relapsing forms) and Crohn's Disease
Key assets Tysabri (natalizumab)
Mechanism Anti-VLA-4 (alpha-4 integrin) monoclonal antibody

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals